Formats
  1. Journal Article (66747)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (661)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5599)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115372)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The prognostic value of pre- and post-neoadjuvant chemotherapy serum carcinoembryonic antigen levels in patients having resection of colorectal liver metastases
    Meeting Abstract

    Song, Y.; Kalvin, H.; Wei, A. C.; Soares, K. C.; Kingham, T. P.; Drebin, J. A.; Jarnagin, W. R.; Gonen, M.; D'Angelica, M. I.
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Timing of adjuvant immunotherapy in stage III melanoma, does it matter?
    Meeting Abstract

    Rhodin, K. E.; Jung, S. H.; Elleson, K.; DePalo, D.; Straker, R.; McKinley, S.; Beekman, K.; Parker, L.; Chen, S.; Salama, A.; more...
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
    Meeting Abstract

    Bullock, A.; Fakih, M.; Gordon, M.; Tsimberidou, A.; El-Khoueiry, A.; Wilky, B.; Pimentel, A.; Margolin, K.; Mahadevan, D.; Balmanoukian, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial
    Meeting Abstract

    Wainberg, Z.; Melisi, D.; Macarulla, T.; Cid, R. P.; Chandana, S.; de la Fouchardiere, C.; Dean, A.; Kiss, I.; Lee, W.; Goetze, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Meeting Abstract

    Sangro, B.; Chan, S.; Kelley, R.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; De Toni, E.; Furuse, J.; Kang, Y.; Galle, P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes and a prognostic classifier in 130 patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade
    Meeting Abstract

    Randon, G.; Aoki, Y.; Cohen, R.; Nasca, V.; Klempner, S.; Maron, S.; Cerantola, R.; Fornaro, L.; Ambrosini, M.; Manca, P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis
    Meeting Abstract

    Tabernero, J.; Van Cutsem, E.; Yoshino, T.; Yaeger, R.; Wasan, H.; Desai, J.; Ciardiello, F.; Alkuzweny, B.; Zhang, X.; Guenzil, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial
    Meeting Abstract

    Valle, J.; Abou-Alfa, G.; Kelley, R.; Lowery, M.; Shroff, R.; Bian, Y.; Saint-Hilary, G.; Liu, H.; Teng, Z.; Hua, Z.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
    Meeting Abstract

    Cowzer, D.; Capanu, M.; Keane, F.; Khalil, D.; Shia, J.; Do, R.; Chou, J.; Walch, H.; El Dika, I.; Yaqubie, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune checkpoint inhibitor (ICI) therapy
    Meeting Abstract

    Keane, F.; Cowzer, D.; Khalil, D.; Shia, J.; Do, R.; Folorunso, S.; El Dika, I.; Yaqubie, A.; Kim, T.; O'Reilly, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save